Keyphrases
Anemia
22%
Boceprevir
24%
Chronic Hepatitis B
79%
Chronic Hepatitis C
47%
COVID-19
57%
Daclatasvir
29%
Direct-acting Antivirals
24%
Entecavir
49%
Gene Polymorphism
22%
Genotype
38%
Genotype 1
17%
Genotype E
38%
GS-331007
21%
HBeAg-negative
22%
Hepatitis B e Antigen (HBeAg)
19%
Hepatitis B Surface Antigen (HBsAg)
19%
Hepatitis C Virus
43%
Hepatitis C Virus Genotypes
18%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
36%
Hospitalized Patients
29%
IL28B
34%
Interferon-free Therapy
20%
Interferon-α (IFN-α)
21%
Italy
29%
Mixed Cryoglobulinemia
28%
MS Method
35%
Multivariate Analysis
20%
Nave
42%
Odds Ratio
17%
Pathway Genes
25%
Peginterferon
21%
Pegylated Interferon
59%
Peripheral Blood Mononuclear Cells
36%
Pharmacogenetics
44%
Plasma Concentration
60%
Plasma Parameters
17%
Polymorphism
23%
Retrospective Analysis
31%
Ribavirin
100%
Ritonavir
16%
Rs12979860
21%
Rs8099917
23%
SNP
18%
Sofosbuvir
38%
Sustained Virological Response
28%
Telaprevir
39%
Tenofovir
21%
Triple Therapy
22%
Virological Response
32%
Vitamin D Pathway
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adult Respiratory Distress Syndrome
11%
Adverse Event
13%
Anemia
17%
Antivirus Agent
27%
Boceprevir
24%
Chronic Hepatitis B
78%
Chronic Hepatitis C
42%
Coronavirinae
41%
Cryoglobulinemia
16%
Daclatasvir
30%
Dasabuvir
16%
Disease
18%
Diseases
33%
Entecavir
49%
Fibrosis
13%
Hepatitis B
17%
Hepatitis B Antigen
35%
Hepatitis B Virus
76%
Hepatitis B(e) Antigen
37%
Hepatitis C
18%
Hepatitis C Virus
26%
Hepatitis C Virus Genotype 1
27%
Hospital Mortality
16%
Infection
55%
Interferon
38%
Liver Cirrhosis
16%
Ombitasvir
16%
Paritaprevir
16%
Peginterferon
54%
Peginterferon Alpha
14%
Pharmacogenetics
39%
Pharmacokinetics
29%
Polyethylene Glycol
17%
Prevalence
16%
Prospective Study
17%
Proteinase Inhibitor
16%
Remdesivir
11%
Ribavirin
91%
Ritonavir
16%
SARS Coronavirus
15%
Simeprevir
11%
Sofosbuvir
35%
Syndrome
16%
Telaprevir
39%
Telbivudine
14%
Tenofovir
21%
Tenofovir Disoproxil
12%
Ultra High Performance Liquid Chromatography
13%
Virus DNA
12%
Vitamin D
33%
Medicine and Dentistry
Adverse Event
5%
Amino Acid
5%
Anemia
7%
Antivirus Agent
11%
Chronic Hepatitis
7%
Chronic Hepatitis B
18%
Chronic Hepatitis C
11%
Cohort Effect
7%
Corticosteroid Therapy
7%
COVID-19
23%
Daclatasvir
11%
DNA Polymorphism
6%
Entecavir
11%
Erythrocyte
6%
Fibrosis
8%
Health Care
12%
Hepatitis B
7%
Hepatitis B Antigen
7%
Hepatitis B Virus
28%
Hepatitis B(e) Antigen
6%
Hepatitis C
11%
Hepatitis C Virus
16%
Hepatitis C Virus Genotype 1
12%
Hospital Mortality
6%
Human Immunodeficiency Virus
7%
Infection
34%
Interferon
25%
Liver Cirrhosis
9%
Liver Fibrosis
7%
Logistic Regression Analysis
6%
Methylprednisolone
5%
Mixed Infection
9%
Observational Study
6%
Odds Ratio
9%
Peginterferon
10%
Pharmacogenetics
6%
Polyethylene Glycol
17%
Prevalence
8%
Prospective Study
11%
Receptor Gene
5%
Retreatment
9%
Ribavirin
42%
Severe Acute Respiratory Syndrome Coronavirus 2
15%
Side Effect
6%
Simeprevir
7%
Single Nucleotide Polymorphism
8%
Sofosbuvir
14%
Tenofovir
5%
Velpatasvir
7%
Virus DNA
6%
